This new treatment provides adults living with schizophrenia a long-acting formulation that offers flexible 1- and 2-month dosing intervals1 In a Phase 3 clinical trial, UZEDY demonstrated
(BPT) - The story you are about to read may not be representative of all people living with schizophrenia. The opinions expressed here are those of Robert, a person living
"I’m 44 years old and live with major depressive disorder (MDD), and it always feels somewhat risky to open up about it. I never know how people will react or if they will look at me differently."
- Approval marks fourth indication for VRAYLAR, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive.